← Back to Funding Now

United States / Direct investor

Breakout Ventures

Backing companies built on science.

Early-stage venture investing in biology, chemistry and technology that turns scientific work into products.

Connect Now
First-cheque rangeNot disclosed
Latest fund$114M Fund III
Portfolio29 relationships
HeadquartersSan Francisco, US

01 / The fund

Science-led investing, from seed onward

Breakout Ventures focuses on science-driven companies using technology, biology and chemistry. Its portfolio includes biological research tools, medicines, industrial biotechnology, advanced materials, sensors and laboratory automation.

The firm announced the close of its $114 million Fund III on March 10, 2026 and said it was actively making seed investments. This is the size of one fund, not a claim about total assets under management.

Official fund overview ↗ · Fund III announcement ↗ · Fund on X ↗

02 / Portfolio

Explore by sector

All 29 companies currently listed in the fund's directory, including historical relationships. Inclusion does not mean every holding remains active or independent. Exit labels below come from Breakout; company-event sources explain later changes.

BioTech 18

Noetik ↗

Uses machine learning and measurements from human tumors to study cancer biology and develop medicines.

Holding source ↗
Vitra Labs ↗

Develops methods to mature eggs outside the body for fertility treatment; its current platform is preclinical.

Holding source ↗
Epana ↗

Uses genomics and AI to develop treatments targeting the immune cells that drive autoimmune disease.

Holding source ↗
A-Alpha Bio ↗

Measures large numbers of protein interactions to help researchers discover and develop medicines.

Holding source ↗
Amaryllis Therapeutics ↗

Develops small protein-like molecules that carry medicines to particular tissues, starting with the brain.

Holding source ↗
Atometra ↗

Automates chemical analysis to support drug research, starting with tools that identify molecules by mass. This focus is described by Breakout.

Holding source ↗
CellChorus ↗

Images individual living cells over time to measure how immune cells interact and respond.

Holding source ↗
Checkerspot ↗

Ferments microalgae to make specialized fats and oils for nutrition, health and other products.

Holding source ↗
Cortexyme (now IRulya) ↗Exited; IPO 2019

Historically developed medicines targeting causes of neurodegenerative disease. The public company later became Quince and then IRulya.

Holding source ↗

Current IRulya logo shown.

Company name changes ↓
Ecovative Design ↗

Grows mycelium, the root-like structure of fungi, to make food, textiles and other products.

Holding source ↗
EnPlusOne ↗

Uses engineered enzymes to make RNA, molecules that carry and control genetic instructions, for research and medicines.

Holding source ↗
Forecast Bio ↗

Uses small laboratory-grown models of brain cells to support neuroscience drug research, according to Breakout.

Holding source ↗
Immusoft ↗

Engineers a patient's immune cells, known as B cells, to produce therapeutic proteins inside the body.

Holding source ↗
Parallel Bio ↗

Builds small models of the human immune system from cells to test and discover medicines.

Holding source ↗
Passkey Therapeutics ↗

Uses computational genetics to identify combinations of medicines that may work better together.

Holding source ↗
Surf Bio ↗Exited; acquired by Halozyme, December 2025

Developed technology to stabilize and concentrate biologic medicines for easier delivery.

Holding source ↗ Acquisition confirmation ↗
TFC Therapeutics ↗

Develops biologic medicines intended to target cancer recurrence and spread.

Holding source ↗
ZymoChem ↗

Uses engineered microbes and fermentation to make bio-based chemicals and polymers.

Holding source ↗

Physical AI 7

Phantom Neuro ↗

Develops investigational implantable sensors that read muscle signals to control robotic devices.

Holding source ↗
Reach Industries ↗

Computer vision captures laboratory work to help teams track experiments and improve workflows.

Holding source ↗
General Sense ↗

Combines animal scent detection, sensors and machine learning to identify chemical signatures.

Holding source ↗
Constellation ↗

Pairs real-world sensors with machine learning to model human physiology, behavior and surroundings.

Holding source ↗
Cytovale ↗

A blood-testing instrument measures physical properties of immune cells to help clinicians assess sepsis risk.

Holding source ↗
ShiraTronics ↗

Develops an implantable electrical stimulation device intended to treat chronic migraine.

Holding source ↗
Transfyr ↗

Captures laboratory actions, surroundings and instrument results to make scientific work easier to understand and repeat.

Holding source ↗

Energy & Materials 4

Twelve ↗

Uses electricity-driven chemical reactions to turn captured carbon dioxide into chemicals, materials and fuels.

Holding source ↗
AquaPoro ↗

Water-harvesting systems capture moisture from air to produce drinking water for homes and industry.

Holding source ↗
Copernic Catalysts ↗

Uses computational tools and laboratory testing to develop catalysts, materials that speed reactions, for ammonia and other industrial chemicals.

Holding source ↗
Modern Meadow ↗

Combines biology and materials science to develop alternatives to conventional materials.

Holding source ↗

03 / Team & connect

Investment team

Public work contacts checked November 17, 2026. No guessed email addresses or X handles are shown. Jerry's email comes from his public July joining post, also reshared by the firm; his current role comes from the fund's team page.

04 / Fund network

Operating support

Rebecca Nugent, PhD

Rebecca Nugent, PhD

Operating Partner

Helps portfolio companies commercialize scientific products. Her biography explicitly says she remains an operator rather than becoming a full-time investor.

Venture partners

Technical and commercial specialists listed by the fund, separate from its full-time investment contacts.

The current team page lists Nima Ronaghi among venture partners. The March 2026 Fund III release described a promotion to Partner; the current page determines his placement here. Finance, legal and platform staff are not presented as investment contacts.

Named Fund III limited partners

The Fund III announcement names Cortes Capital, S-Cubed Capital, The Kraft Group, Pinegrove Venture Partners, an affiliate of LH Capital, JIMCO and Korea Omega Investment Corporation. These are named examples, not a complete limited-partner list.

Fund III limited-partner source ↗

Who's raising. Who's funding. What's next in DeepTech.